Redeye comments on Medivir’s Q2 report. The quarter was somewhat uneventful, but the company has made further progress and is essentially ready for the planned pivotal phase II study in liver cancer. The only thing missing is funding.
ANNONS
Redeye comments on Medivir’s Q2 report. The quarter was somewhat uneventful, but the company has made further progress and is essentially ready for the planned pivotal phase II study in liver cancer. The only thing missing is funding.